Profound Medical Corp.

Profound Medical is a commercial-stage medical technology company that develops and markets incision-free, magnetic resonance imaging-guided thermal ablation systems for diseased tissue. Its core product, the TULSA-PRO system, delivers robotically driven ultrasound to treat benign and malignant prostate conditions, including prostate cancer and benign prostatic hyperplasia. The company also provides the Sonalleve system, which utilizes focused ultrasound to treat uterine fibroids, osteoid osteoma, and bone metastases. Profound operates through capital equipment sales and recurring revenue from single-use procedural devices and maintenance services. Its customer base consists primarily of specialized physicians, such as urologists and radiologists, at hospitals and outpatient imaging facilities.

The company conducts commercial operations across the United States, the European Union, Canada, and Asian markets including China and South Korea, with additional device registrations in the Middle East and Southeast Asia. Its platform technologies interface with magnetic resonance imaging systems from global diagnostic imaging manufacturers. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Profound Medical's latest annual report, written by StockData.

“As of December 31, 2025, we had 162 employees, all of whom were full-time employees.”